Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Inhaled KB407, a Replication-Incompetent, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), for the Treatment of Cystic Fibrosis

Next Previous
X
Search
Trial Profile

A Phase I Study of Inhaled KB407, a Replication-Incompetent, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), for the Treatment of Cystic Fibrosis

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KB 407 (Primary) ; KB 407 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Krystal Biotech

    • Most Recent Events

    • 09 Aug 2023 Status changed from recruiting to withdrawn prior to enrolment.
    • 08 May 2023 According to a Krystal Biotech media release, screening activities are ongoing.
    • 05 Jun 2022 Planned End Date changed from 30 May 2022 to 30 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top